07.20.18

CorneaGen: New Studies Prove Kamra Inlay is a Safe and Effective Treatment for Presbyopia

Source: CorneaGen
Two recently completed studies conducted by four refractive surgeons prove the safety and long-term effectiveness of the »Kamra Inlay, a mini-ring that restores functional near vision when implanted in the cornea, according to a CorneaGen news release.
 
Dr. Mitsutoshi Ito in Japan and Dr. Majid Moshirfar, Dr. Luke Rebenitsch and Dr. Phillip Hoopes, Jr. in the United States followed a combined total of 2,969 patients in their respective studies. The surgeons agree that the Kamra Inlay is an important tool that can be used in combination with LASIK—instead of monovision—to effectively treat presbyopia and help build relationships with patients as their eyesight naturally changes throughout their lives. The Kamra Inlay was acquired from Acufocus in March 2018 by CorneaGen.
 
“Offering the Kamra Inlay helps me maintain a long-term relationship with my patients,” Dr. Mitsutoshi Ito of Shinagawa LASIK Center in Tokyo, where more than 12,000 KAMRA Inlay procedures have been performed since 2009, said in a company news release. “Patients I’ve treated with LASIK often come back to me in their 40s looking for an alternative to reading glasses. With careful patient education, the Kamra Inlay can provide both near and far vision. This success encourages them to return to me as they age and progress to the next stage of their spectacle-free life.”  
 
Dr. Ito’s study involved 2,843 patients treated between May 2011 and January 2014 with a two-stage procedure: LASIK followed by implantation of the Kamra Inlay a week or more later. The outcome of the procedure and satisfaction of each patient was followed for more than 4 years. Impressivley, less than 7 percent of the study patients later had the Kamra Inlay removed, and this number includes those who developed diseases such as early cataracts, epiretinal membrane and glaucoma, which necessitated implant removal. Overall, the number of patients who could not adapt to extended depth of focus required by Kamra or who were unhappy with other Kamra-related visual symptoms was much less than Dr. Ito anticipated.
 
A restrospective U.S. study conducted in 2017 by Dr. Phillip Hoopes, Jr. and Dr. Majid Moshirfar of Hoopes Vision in Draper, Utah, and Dr. Luke Rebenitsch of ClearSight Center in Oklahoma City, Okla., also confirmed that the Kamra Inlay is safe and effective. The three surgeons followed a total of 126 of their patients who received the Kamra Inlay either in a simultaneous LASIK/inlay surgery or in a simultaneous PRK/inlay surgery to treat presbyopia.
 
“When the FDA approved the Kamra Inlay in 2015, the study included a narrow range of patients: people who only wore reading glasses,” says Dr. Hoopes, Jr. “Our study shows that as long as you combine the Kamra procedure with a refractive surgery, people with prescriptions do just as well and have equal safety as patients in the original study group.”
 
Dr. Rebenitsch said, “Presbyopia has historically been difficult to treat. There have been few solutions, and none that worked for everyone. The fact that the Kamra Inlay can provide functional near vision with minimal effect on distance vision is very appealing to my patients.”
 
The Kamra Inlay is part of CorneaGen’s growing line of therapeutics for corneal surgeons. Other new products include tissue storage media with antifungal Ampho B, the Geuder Preloaded Glass Cannula for DMEK, and Intacs corneal implants for keratoconus. For more information, visit www.corneagen.com.
 

Related Content